Key Takeaways

  • Livsayis (cemdisiran) is the first siRNA therapy approved for generalized myasthenia gravis, dosed once every three months
  • In the NIMBLE trial it beat placebo by an adjusted 2.3 points on the MG-ADL daily-function scale (p=0.0005)
  • It carries a boxed warning for meningococcal infections and is dispensed under a restricted safety program

A different approach to myasthenia gravis: A drug that switches off an immune protein

What if treating a muscle disease meant switching off just one immune protein?

Myasthenia gravis happens when the immune system attacks the connection between nerves and muscles. The result is weakness that gets worse with use — drooping eyelids, double vision, trouble swallowing, and, in its generalized form, weakness across the body.

That connection is now the target of a new treatment. On November 18, the U.S. Food and Drug Administration approved Livsayis (cemdisiran), from Regeneron — the first siRNA therapy approved for generalized myasthenia gravis, for adults whose disease is driven by anti-acetylcholine receptor antibodies.

Livsayis works upstream. It is a small interfering RNA that silences production of complement C5, one of the immune proteins that damages the nerve-muscle junction — reducing C5 levels by more than 70% in trials. It is given as an injection once every three months.

What happened when researchers tested it?

The approval rests on the Phase 3 NIMBLE trial. On the MG-ADL scale, which measures how the disease affects daily activities, patients on Livsayis improved by 4.5 points at week 24, versus 2.2 points on placebo — an adjusted difference of 2.3 points (p=0.0005). On the physician-assessed QMG strength scale, the adjusted advantage was 2.8 points (p=0.0015).

The drug carries a boxed warning — the FDA's strongest — for meningococcal infections, a known risk of blocking the complement system. It will be dispensed under a restricted safety program (REMS), and patients are vaccinated against meningococcal disease before treatment.

Health note: This is a U.S. approval, not a Health Canada decision. Livsayis is for adults with anti-AChR-positive generalized myasthenia gravis, and its boxed warning means it is prescribed under a formal safety program. Treatment choices in this disease are specialist decisions.

The Twikup Take

siRNA drugs — medicines that switch off a single protein's production — have been a promising idea for a decade. A once-every-three-months injection that beat placebo on both patient-reported and physician-measured scales makes Livsayis the proof of concept in myasthenia gravis, with a serious infection warning that will shape who gets it first.

Image: Illustrative image.

Sources